Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) has entered in to a clinical collaboration agreement with Roche (SIX:RO; OTCQX:RHHBY) to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.
Novartis highlights extensive data on numerous compounds at ASCO
- Details
- Category: Novartis
Novartis will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO).
AstraZeneca and Heptares collaborate to investigate important GPCR drug targets
- Details
- Category: AstraZeneca
AstraZeneca and Heptares Therapeutics have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors (GPCRs).
Sanofi and DNDi - Drugs for Neglected Diseases initiative - Sign an Innovative Agreement
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE:SNY) and Drugs for Neglected Diseases initiative (DNDi) announced a three-year research collaboration agreement for the research of new treatments for nine neglected tropical diseases (NTDs), listed by the World Health Organization (WHO) for which new, adapted, and efficient tools are urgently needed to treat patients in endemic countries.
RoACTEMRA could change the current standard of treatment for people living with rheumatoid arthritis
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced new data from the ACT-RAY study, presented at the European League Against Rheumatism congress. The results demonstrated that in people with rheumatoid arthritis (RA), RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) alone had comparable clinical efficacy to RoACTEMRA plus methotrexate (MTX).
Pfizer Announces New Strategic Partnerships with ICON and PAREXEL International Corporation
- Details
- Category: Pfizer
Pfizer Inc. announced strategic partnerships with ICON plc and PAREXEL International Corporation, both of which will serve as strategic providers of clinical trial implementation services over a five-year period beginning in June 2011.
Major Subgroup Analysis Shows Bayer's Rivaroxaban is Highly Effective in the Prevention of Recurrent Strokes
- Details
- Category: Bayer
A pre-planned subgroup analysis of the ROCKET AF Phase III clinical study confirms that rivaroxaban is highly effective in the prevention of recurrent strokes in patients with atrial fibrillation (AF) who have experienced a prior stroke or transient ischemic attack (TIA).
More Pharma News ...
- Nycomed continues to outperform in emerging markets in first quarter 2011
- GSK forms partnership with three leading NGOs
- AstraZeneca signs agreement in Japan with Daiichi Sankyo to co-promote denosumab
- Lilly and Investor Group Form New Critical Care Company BioCritica
- Sanofi's Commitment to Research and Identify Treatments for Cancer Patients
- SUTENT® Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
- Takeda to Acquire Nycomed - Transaction will Transform Takeda's Global Business